Published in AIDS Weekly, November 17th, 2003
Based upon its current backlog, the company expects to generate revenues of $23 million to $25 million and net income of approximately $5 million. The company does not expect to pay taxes next year as a result of net operating loss carry forwards.
"We continue to generate growing interest in our urine HIV-1 EIA," said Tony Cataldo, Calypte Biomedical's chairman. "In just the last 3 months, the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.